China Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth. With most of the founding teams having returned from extensive careers in the US and the unparalleled innovation potential of…
China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…
China Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs of patients in China and the world. Sinovant Sciences is set up to take an integrated approach to develop…
See our Cookie Privacy Policy Here